These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 19587645)

  • 21. Biotechnology partnerships--medicine for an ailing industry?
    DeLamarter J
    Nat Biotechnol; 2003 Aug; 21(8):847-8. PubMed ID: 12894192
    [No Abstract]   [Full Text] [Related]  

  • 22. Take your partner by the hand..
    Smaglik P
    Nature; 2005 Jun; 435(7046):1281. PubMed ID: 15997477
    [No Abstract]   [Full Text] [Related]  

  • 23. The lengthening handshake.
    Osborne R
    Nat Biotechnol; 2010 Mar; 28(3):197-9. PubMed ID: 20212476
    [No Abstract]   [Full Text] [Related]  

  • 24. This Dutchman is flying.
    Watson N
    Fortune; 2003 Jun; 147(13):89-90. PubMed ID: 12827720
    [No Abstract]   [Full Text] [Related]  

  • 25. The three pillars of bioentrepreneurship.
    Schoemaker HJ; Schoemaker AF
    Nat Biotechnol; 1998 May; 16 Suppl():13-5. PubMed ID: 9591253
    [No Abstract]   [Full Text] [Related]  

  • 26. Row over industry link-up splits staff of Spanish lab.
    Fernandez Hermana LA
    Nature; 1994 Dec; 372(6507):586. PubMed ID: 7990935
    [No Abstract]   [Full Text] [Related]  

  • 27. From the analyst's couch: The outlook for biotech exits.
    Grimaldi A
    Nat Biotechnol; 2014 Mar; 32(3):227-8. PubMed ID: 24727772
    [No Abstract]   [Full Text] [Related]  

  • 28. Biotechs hold their own in shifting industry.
    Mitchell P
    Nat Biotechnol; 2002 Nov; 20(11):1065-6. PubMed ID: 12410238
    [No Abstract]   [Full Text] [Related]  

  • 29. Niche indications could drive higher valuations.
    Ransom J
    Nat Biotechnol; 2006 Dec; 24(12):1457. PubMed ID: 17160028
    [No Abstract]   [Full Text] [Related]  

  • 30. Roche chases stake in medical sequencing.
    Hayden EC
    Nature; 2012 Apr; 484(7393):152. PubMed ID: 22498604
    [No Abstract]   [Full Text] [Related]  

  • 31. Genentech grapples with direct offer.
    Huggett B
    Nat Biotechnol; 2009 Mar; 27(3):212. PubMed ID: 19270652
    [No Abstract]   [Full Text] [Related]  

  • 32. Investing in risk management.
    Fiscus PW
    Nat Biotechnol; 1997 Jan; 15(1):88-9. PubMed ID: 9035113
    [No Abstract]   [Full Text] [Related]  

  • 33. When times get tough.
    Jong S
    Nat Biotechnol; 2009 Mar; 27(3):226-8. PubMed ID: 19274868
    [No Abstract]   [Full Text] [Related]  

  • 34. In search of the élite.
    Gewin V
    Nature; 2003 Dec; 426(6967):713-7. PubMed ID: 14668879
    [No Abstract]   [Full Text] [Related]  

  • 35. Biotech boot camp.
    Ledford H
    Nature; 2015 Mar; 519(7544):402-5. PubMed ID: 25810186
    [No Abstract]   [Full Text] [Related]  

  • 36. Finnish biotechnology--built on solid foundations.
    Lähteenmäki R
    Nature; 2002 Dec; 420(6916 Suppl):A34-5, A37, A39. PubMed ID: 12501125
    [No Abstract]   [Full Text] [Related]  

  • 37. The quiet revolution.
    Nat Biotechnol; 2003 Jul; 21(7):715. PubMed ID: 12833072
    [No Abstract]   [Full Text] [Related]  

  • 38. Biotech's new colossus. Move over, Big Pharma. Amgen boasts better growth.
    Stipp D
    Fortune; 2002 Apr; 145(8):144-6, 148, 150. PubMed ID: 11961884
    [No Abstract]   [Full Text] [Related]  

  • 39. Researchers cut loose as Pfizer and Merck shutter European sites.
    Subbaraman N
    Nat Biotechnol; 2011 Apr; 29(4):299-300. PubMed ID: 21478836
    [No Abstract]   [Full Text] [Related]  

  • 40. Deal watch: M&A activity in 2009.
    Walker J
    Nat Rev Drug Discov; 2010 Feb; 9(2):95. PubMed ID: 20118956
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.